The Precision Genomics Platform for Clinical Diagnostics
Transforming complex sequencing data into actionable clinical insights with cutting-edge bioinformatics and artificial intelligence.
Bridging the gap between cutting-edge research and clinical reality.
Omixir Bioinformatics Pvt. Ltd. is an Indian genomics company developing NGS-based diagnostics, AI-powered analysis platforms, and computational tools for precision medicine.
Our Mission
Make advanced genomic diagnostics more accurate, accessible, and clinically meaningful through the integration of cutting-edge sequencing technologies, bioinformatics, and artificial intelligence.
Our Vision
To build robust genomics analysis platforms enabling earlier diagnosis, better clinical decision-making, and personalized healthcare — making precision medicine accessible to every patient and clinician.
What we specialize in
Comprehensive genomic analysis to detect a wide spectrum of genetic variants involved in a broad range of genetic disorders and diseases.
- Single nucleotide variants (SNVs)
- Insertions & deletions (Indels)
- Copy number variants (CNVs)
- Structural variants (SVs)
- Repeat expansions
- Mitochondrial variants
- Complex genomic rearrangements
- Phenotype-driven prioritization
- Population-aware clinical reporting
Our Solutions
A clinical genomics platform and an AI copilot, engineered together for accuracy and speed.
Assure
Clarity in prenatal rare disease diagnostics.
Assure is Omixir's flagship genomics analysis platform designed to enable comprehensive and accurate detection of disease-associated genetic variants from next-generation sequencing (NGS) data. Powered by Omixir's proprietary analysis pipeline, Assure integrates advanced bioinformatics for variant prioritization, phenotype-driven interpretation, and clinically curated evidence to transform complex genomic data into actionable clinical insights.
- Comprehensive detection of SNVs, indels, CNVs, structural variants, repeat expansions, and mitochondrial variants
- Integrated annotation using ClinVar, OMIM, HGMD, dbSNP, gnomAD, and other leading genomic databases
- Scalable cloud-based computational infrastructure for rapid analysis
Geneie
Your conversational genomics expert.
Geneie simplifies genomic data interpretation for clinicians, researchers, and diagnostic labs — variant interpretation, literature retrieval, phenotype analysis, ACMG support, and report generation through conversational AI.
- Natural language variant interpretation
- Instant literature & ACMG guideline support
- Automated, population-aware genomic reports
Bioinformatics engineered for clinical scale.
Omixir builds scalable workflows on industry-standard tools and modern computational infrastructure — from short- and long-read integration to cloud-based genomic computing.
- Sequencing Integration
- Short-read and long-read sequencing integration across platforms and chemistries.
- Variant Calling & Validation
- Variant calling with orthogonal validation across SNVs, indels, CNVs, and structural variants.
- Structural Variant Analysis
- Dedicated SV callers combined with visualization and manual review workflows.
- ML for Variant Prioritization
- Machine learning models rank variants by pathogenicity and phenotype relevance.
- Clinical Annotation
- ClinVar, OMIM, HGMD, dbSNP, and other clinical databases integrated end-to-end.
- Cloud-Based Compute
- High-performance and cloud-based genomic computing that scales with clinical demand.
Databases & Prediction Models
Clinical annotation, functional prediction, and population genomics — combined into a single interpretation surface.
- ClinVar
- OMIM
- HGMD
- dbSNP
- SIFT
- PolyPhen
- CADD
- SpliceAI
- GenomeIndia
- gnomAD
- HPO
- ACMG
Who We Serve
Trusted across the clinical, research, and industry genomics ecosystem.
- Hospitals
- Genetic Counselors
- Clinical Labs
- IVF Clinics
- Academic Institutions
- Pharma
Get in touch
We'd love to hear from you, whether you're exploring Assure, evaluating Geneie, or looking to partner.
Contact information
Reach us directly through any of the following channels.